Results 331 to 340 of about 3,298,250 (374)

Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes. [PDF]

BMJ Open
Seyed Ahmadi S, Korsgren O, Jansson PA, Lind M.   +3 more
europepmc   +1 more source

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience. [PDF]

Dermatol Reports
Ghezzi G, Ibba L, Gargiulo L, Narcisi A, Costanzo A, Valenti M.   +5 more
europepmc   +1 more source

Longer Drug Retention of Interleukin-12/23 or Interleukin-17 Inhibitors Compared With TNF Inhibitors in Female Patients With TNF Inhibitor-Experienced Psoriatic Arthritis. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Scholz GA, Papagiannoulis E, Blapp C, Micheroli R, Ciurea A, Nissen MJ, Yawalkar N, Dan D, Amsler J, Scherer A, Möller B.   +10 more
europepmc   +1 more source

Interleukin-4 and Interleukin-17 are associated with coronary artery disease. [PDF]

Clin Cardiol
Wang C, Liu S, Yang Y, Kamronbek R, Ni S, Cheng Y, Zhou C, Yan H, Li L, Liu H, Wang Y, Qin Y, Yin C, Zhang M.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interleukin-17 in Liver Disease Pathogenesis

Seminars in Liver Disease, 2021
AbstractInterleukin 17A (IL-17A)-producing T helper 17 (Th17) cells were identified as a subset of T helper cells that play a critical role in host defense against bacterial and fungal pathogens. Th17 cells differentiate from Th0 naïve T-cells in response to transforming growth factor β1 (TGF-β1) and IL-6, the cytokines which also drive development of ...
Na, Li, Gen, Yamamoto, Hiroaki, Fuji, Tatiana, Kisseleva   +3 more
openaire   +3 more sources

Interleukin 17 Inhibitors

2021
Margot A. Chima, Mark G. Lebwohl
openaire   +2 more sources

Interleukin-17

International Reviews of Immunology, 1998
The particular interest of IL-17, a homodimeric cytokine of about 32 kDa, is the strict requirement for an activation signal to induce its expression from a rather restricted set of cells, human memory T cells or mouse alpha beta TCR+CD4-CD8- thymocytes.
F, Fossiez, J, Banchereau, R, Murray, C, Van Kooten, P, Garrone, S, Lebecque   +5 more
openaire   +2 more sources

Interleukin-17

Encyclopedia of Molecular Pharmacology, 2021
C. Huppertz
openaire   +2 more sources

Measurement of Interleukin‐17

Current Protocols in Immunology, 2007
AbstractUpon antigenic stimulation, naive CD4+ T cells undergo proliferation and differentiate into cytokine‐producing T helper (TH) effector cells. TH1 cells secrete effector cytokine IFN‐γ and regulate cell‐mediated immunity, whereas TH2 cells produce IL‐4, IL‐5, and IL‐13 cytokines, and mediate immunity against extracellular pathogens and allergic ...
Bhanu P, Pappu, Chen, Dong
openaire   +2 more sources

Interleukin-17 in Inflammatory Myopathies

Current Rheumatology Reports, 2012
Since the identification of interleukin (IL)-17 as a T-cell-derived cytokine 15 years ago, the contribution of the T-helper type 17 (Th17) pathway in inducing and maintaining chronic inflammation has been well-established, particularly in rheumatoid arthritis. In addition to the main Th1 profile first suggested to contribute to inflammatory myopathies,
Anne, Tournadre, Pierre, Miossec
openaire   +2 more sources